Fyrol ex resorcinol bis-diphenylphosphate (RDP) is a nonhalogen phosphate ester product that is widely used as a ame retardant for petrochemicalplastics and high-temperature lubricant additive applications. The potential developmental toxicityof RDP was evaluated in rabbits. Groups of 27 sperm-positive New Zealand white rabbits (Hazelton Research Products Inc., Denver, PA) were administered graded concentrations of 50, 200, or 1000 mg/kg/day of RDP in corn oil. A vehicle control group of equal size was administered corn oil alone. Rabbits were dosed daily (1.5 ml/kg) on gestationdays 6 to 28 and sacri ced on gestationday 29. The fetuses were removed by cesarean section and examined for gross external, visceral,cephalic, and skeletal anomalies.No treatment-related clinical signs of toxicity were observed. No treatment-relatedeffects in maternal food consumption, body weight, body weight gain, or on uterus, liver, kidney, and spleen weights were detected. Fetal viability and body weight, as well as developmental end points were also unaffected by treatment. Accordingly, exposure of pregnant rabbits to doses ranging from 50 to 1000 mg/kg/day of RDP during the periods of major organogenesis and histogenesis did not result in any biologically signi cant toxic or teratogenic/developmental effect in the dams or fetuses.
triaryl phosphate esters were used to impart ame retardancy to plastic resins. However, triaryl phosphate esters proved to be unstable when used under new manufacturing processes requiring higher temperatures for resin compounding and molding. Therefore, RDP replaced the triaryl phosphate esters. RDP provides excellent ame retardancy without causing defects in the molded resin products.
The production of Fyrol ex RDP is performed under a closed system, and worker exposure is limited to the sampling and packaging operations. A multistudy program was designed to evaluate the potential toxicity of this product as well as provide a comprehensive safety assessment pro le. The program assessed the developmental, reproductive, immunotoxicity, and respiratory toxicityof RDP as well as its metabolismand toxicokinetics. Each of the ve evaluations are reported in this journal as companion papers. This study was speci cally designed to evaluate the potential of RDP to alter fetal development following oral (gavage) administration of RDP to pregnant New Zealand white rabbits during organogenesis and histogenesis (gestation days 6-28). The design was based on revised draft testing guidelines set forth under the Of ce of Prevention, Pesticides and Toxic Substances (OPPTS) (870.3700), which blend the testing guidance and requirements of the Of ce of Pollution Prevention and Toxic Substances (OPPT), the Of ce of Pesticide Programs (OPP), and the Organization for Economic Cooperation and Development (OECD) .
were prepared in a corn oil vehicle by preparing individualdoses. Individual doses were prepared daily by drawing the required volume of RDP into a glass syringe and the required volume of corn oil into a plastic syringe and mixing the contents of the two syringes using a stopcock connector. The nal mixture of corn oil-RDP was pushed into the plastic syringe and then a gavage needle was attached to the plastic syringe for administration of the dosing suspension via oral gavage to the rabbits.
Animals
New Zealand white rabbits (Hazleton Research Products
[HRP] Inc., Denver, PA) were used in this study. At mating, female rabbits were approximately 5 months old, and males ranged in age from 6 to 29.5 months. Males were used for mating purposes only and were not dosed with test substance. All animals were single-housed in stainless steel cages and quarantined for 2 weeks after receipt, and then examined for suitability for use as test animals. During quarantine, females were intubated with water for acclimatization purposes. During mating, one male and one female rabbit were housed together in stainless steel wire mesh cages suspended over cage boards or absorbent paper. After mating (determined by a sperm-positive vaginal imprint), females were removed and single-housed for the remainder of the study. Animal rooms were maintained at 18-25 ± C and 30-70% relative humidity. Lights were cycled 12 hours on and 12 hours off. Food (a 50:50 mixture of Certi ed High Fiber and Certied Rabbit Chow; PMI Feeds, Inc., St. Louis, MO) and City of Chicago municipal tap water were provided ad libitum.
Experimental Design
The day of a sperm-positive vaginal imprint from a female rabbit was designated gestation day 0 for that doe. On that day, the doe was weighed and that weight used for randomization of animals into four groups with 27 sperm-positive does in each group. The low-, mid-, and high-dose groups received 50, 200, or 1000 mg RDP per kg body weight per day, respectively, in corn oil by oral gavage. The vehicle control group received corn oil only by oral gavage. Treatment was initiated on gestation day 6 for each respective doe, and continued through gestation day 28. Each doe was sacri ced on gestation day 29.
Clinical Observations
All rabbits were examined once or twice each day for morbidity and mortality. Physical examinationswere performed prior to randomization and prior to sacri ce. In addition, does were observed for signs of toxicity 0 to 3 hours after dosing on gestation days 6 through 28.
Body Weight, Body Weight Gains, and Food Consumption
All does were weighed on gestation days 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 29 . Food consumption was also monitored during gestation days 0 to 29, with feeders being weighed on gestation days 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 29 .
Postmortem Observation
The does were humanely euthanizedusing an anestheticoverdose of sodium pentobarbitaland subjected to a cesarean section and gross necropsy to determine their pregnancy status and the presence of lesions and/or abnormal conditions in the does or fetuses. The liver, spleen, and kidneys were removed from each rabbit at necropsy, trimmed of excess fat, and weighed. The uterine horns, fetuses, and ovaries were removed intact,trimmed free of adherent tissue, and weighed. The number of corpora lutea in each ovary were counted and recorded. Fetuses were excised from the uterine horns and individually weighed after the total number and dispositionof each implant was recorded. Each fetus received a gross external morphologic examination. All fetuses received a wet visceral examination by a modi ed method of Staples (Stuckhardt and Poppe 1984) . Approximately one third of each litter was randomly assigned to be decapitated.The heads were examined using a modi ed Wilson's razor blade sectioning technique (Wilson 1965) . All fetal carcasses, including those of the decapitated pups, were processed for skeletal evaluations. All anomalies were classi ed as variations or maliformations; all life-threatening conditions as well as any permanent structural deformities were classi ed as a malformation. In-house standard operating procedures de ne/describe commonly encountered malformations and variations. In addition, all skeletal anomalies were given a severity score ranging from 1 to 4, with a score of 1 equivalent to a variation within normal limits, a score of 2 indicative of a slight variation, a score of 3 indicative of a moderate variation, and a score of 4 indicative of a sever variation. Skeletal malformations were given a score of 5.
Statistical Procedures
Means and standard deviations were calculated for all measured parameters. Doe body weight, body weight gain, food consumption, uterus weight, organ weight, body weight, body weight gain, and fetal weight were analyzed by a multivariate analysis of variance. Analyses were performed using LABCAT (IPA, Inc., Princeton, NJ, version 4.64) for doe body weight, body weight gain, and food consumption;and Systat (SPSS, Inc., Chicago, IL, version 5.0) for uterus weight, organ weight, body weight, and body weight gain, corrected for uterus weight and fetal weights. For viability data, a one-factor (i.e., treatment group) ANOVA was used for log corpora lutea, total implants, the percent live implants {logit transformed; (relative live + 0.5)/[(1 ¡ relative live) + 0.5]}, the percent resorptions {logit transformed; (relative resorption + 0.5)/[(1 ¡ relative resorption) + 0.5]}, and percent preimplantation loss. In the presence of signicant main effects, all post hoc comparisons between the test substance-treated and vehicle control group were conducted using the Dunnett's test. Skeletal, visceral, and gross external malformation data were statistically analyzed by chi-square and Fischer exact tests when the incidence in the treated groups was higher than controls (i.e., difference of greater than 3). A minimum signi cance level of p · .05 was used in the comparisons.
RESULTS

Morbidity, Mortality, and Clinical Observations
None of the female rabbits died during the study, and there were no dose-related clinical observations among the test substance-treated animals (data not shown). Two premature deliveries (delivered prior to gestation day 29) occurred in the 50 mg/kg group, and one doe in the 200 mg/kg group underwent parturition on gestation day 29 (full-term delivery).
Body Weight, Body Weight Gain, and Food Consumption
No signi cant differences were detected in body weights (Figure 1 ), corrected body weight, or corrected body weight gains for the test substance-treated groups compared to controls during the course of the study. Occasional and isolated signicant increases in body weight gains and food consumption were
FIGURE 1
Average gestating doe body weight. noted in the high-dose group relative to the control group, but these were not considered biologically relevant (Table 1) .
Organ Weights
No signi cant differences were observed in liver, kidney, or spleen weights for the RDP treated groups compared to controls (Table 2 ). In addition, gravid uterus weights were similar across all groups.
Postmortem Observations
There were no gross pathological abnormalities in any of the dams in the test substance-treated groups. One rabbit in the control group had a mass in the left fallopian tube.
Litter Viability and Fetal Body Weights
There were no signi cant differences among the groups in live implants, total implants, or resorptions. There also were no signi cant differences among groups in corpora lutea or in preimplantation loss (Table 3 ). The greatest number of dead fetuses occurred in the high-dose group, but was associated with deaths occurring in a single litter and was considered a cluster effect within that litter. There also were no signi cant differences among the groups in the litter male-to-female ratios. No significant differences were present in mean fetal body weights for males, females, or combined sexes, as compared to the vehicle controls (Table 4) .
Fetal Evaluations (Gross External, Wet Visceral, Skeletal, and Cephalic)
Gross external appearance of all fetuses was unremarkable, except for one vehicle control fetus that had a misshaped hindlimb. Skeletal evaluation of the hindlimb from this fetus was unremarkable; the abnormal limb was most likely a deformation resulting from uterine position, or may have been an artifact of handling/processing prior to the gross external evaluation (Table 4 ). Visceral evaluations were low in incidence and distributed across groups (Table 4 ). Heart vessel defects were observed as follows: a common truncus (classi ed as a malformation) in one mid-dose pup, short/absent innominate in one pup each in the vehicle control, mid-, and high-dose groups, and abnormal branching of the subclavian in one pup in the control and two litter mates in the low-dose group. In addition, small lungs were noted in one low-dose group fetus. The incidence of the aforementioned anomalies ranged from a fetal/litter incidence of approximately 0.46% (i.e., 1 fetus/group) to 0.93% (i.e., 2 fetuses/group) and a litter incidence of 4% (i.e., 1 litter/group) to 8% (i.e., 2 litters/group). Cephalic anomalies were also low in incidence and were distributed across the test substance treated groups. A total of one fetus in each of the lowand mid-dose groups, and three fetuses among two litters in the high-dose group had cephalic anomalies; multiple anomalies were noted in one of the three affected high-dose fetuses. Cephalic observations (Table 4) consisted of: unilateral dilatation of the ventricle (one fetus in both the mid-and high-dose groups), slight hypoplasia of the diencephalon (one low-and one high-dose fetus), convoluted retina (two high-dose fetuses), and one ectopic lens (one high-dose pup). The high-dose fetus with hypoplasia of the diencephalon also had an ectopic lens and a convoluted retina.
Most of the skeletal observations (e.g., sternebrae, centrae anomalies, 13th rib anomalies) consisted of common variations with a range of normal occurrences unrelated to treatment with the test substance ( Table 5 ). The incidence of rabbit fetuses with a normal full length 13th rib was greater in the high-dose group than in the control. Although this seems to be an apparent shift in the number of rib pairs, it must be noted that the number of ribs is genetically determined and considered a normal variant (Harris and DeSesso 1994) . Fused sternebrae were noted in one low-dose fetus and three mid-dose fetuses. The incidence of pups with skeletal malformations were 1/217, 2/216, 1/215, and 0/219 in the vehicle control, low-, mid-, and high-dose groups, respectively. The skeletal malformations consisted of: fused ribs (one control and one low-dose group fetus), forked ribs (one lowdose fetus), and absence of lumber vertebral arch (one mid-dose fetus). No skeletal anomalies were observed in the high-dose group.
The total number of fetuses with any combination of malformations determined from gross external, visceral, cephalic, or skeletal examinations were 1/217, 3/215, 3/215, and 3/219 in the control, low-, mid-, and high-dose groups, respectively. There were no signi cant differences among the groups in the number of malformed fetuses or in the percentage of live fetuses that were malformed (Table 3 ). In addition, the fetal incidence noted for anomalies in all groups was similar to or below published historical control values for these anomalies as published by the Middle Atlantic Reproductive and Teratology Association (MARTA) and the Midwest Teratology Association (MTA) ( Table 6 ).
DISCUSSION
Exposure of pregnant rabbits to RDP via oral gavage at concentrations of 50, 200, or 1000 mg/kg/day during the periods of major organogenesis and histogenesis (i.e., days 6 through 28 of gestation) did not result in any biologically signi cant alterations in fetal or maternal body weights, nor in any gross external, skeletal, or visceral anomalies in the fetuses No clinical signs of maternal toxicity were evident during the study or were apparent from gross necropsy observations. Mean body weights, body weight gains, food consumption, uterus weights, and organ weights showed no test substance-related effects. There were no signi cant differences in fetal (litter) body weights observed between the test substance-treated groups and the vehicle control, nor were there any signi cant increases in fetal deaths, resorptions, or malformations between the test substance-treated groups and the control group. The visceral, cephalic, and skeletal malformations observed were low in incidence and sporadic in nature, and were not considered test substance-related, because no clear pattern or relationship between the affected structure and dose group could be established. No dose-response relationship was evident from the incidence of visceral anomalies, because the highest number of pups affected was in the low-dose group and similar incidences of visceral anomalies were observed in the control and highdose groups. Cephalic anomalies were observed only in test substance-treated groups, but the sporadic distribution of these anomalies and lack of correlation between types of anomalies and dose level clearly indicate that these were spontaneous in nature and unrelated to treatment. For skeletal malformations, the highest incidence occurred in the low-dose group and no malformations were observed in the high-dose group. Thus, a dose-response relationship was not evident.
Further evidence that RDP had no effect on the incidence of fetal anomalies is based on historical control data on the incidence of anomalies in New Zealand white rabbits compiled by the MiddleAtlanticReproductiveand Teratology Association and the Midwest Teratology Association (MARTA and MTA 1993; 1996. Published and distributed by HRP Inc.). Incidence of the observed visceral, cephalic, and skeletal anomalies among fetuses in this study is similar to the historical control values reported by MARTA/MTA.
In conclusion, administration of RDP to pregnant rabbits at dose levels up to 1000 mg/kg body weight/day did not result in any developmental toxicity.
